Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + tislelizumab
- Development stage
- Phase 2
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Surufatinib + tislelizumab is an investigational combination therapy for advanced solid tumors. Surufatinib is a novel, oral small molecule angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptor (FGFR), and colony stimulating factor 1 receptor (CSF-1R). This results in inhibition of angiogenesis and modulation of tumor-associated macrophages, promoting immune response against tumor cells. Tislelizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 to restore T-cell function and enhance anti-tumor immunity. The combination aims to leverage potential synergistic effects between antiangiogenic and immunotherapy mechanisms for improved efficacy in various cancers, including neuroendocrine tumors, colorectal cancer, small cell lung cancer, gastric cancer, and soft tissue sarcoma[2][4][8].
- Brand names
- Baizean
- Other names
- surufatinib + tirelizumabHMPL-012 + BGB-A317
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on surufatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + tislelizumab.